The White House plans to announce a drug pricing pact with Regeneron Pharmaceuticals at a Thursday afternoon event, a development flagged publicly by White House press secretary Karoline Leavitt in a post on X. Regeneron is the final member of a group of 17 major pharmaceutical companies that received letters from President Donald Trump in July and had been asked to reach pricing agreements.
The company confirmed that the agreement will be unveiled at the scheduled event. In morning trading on the stock market, Regeneron shares rose by more than 2%.
The reported deal follows similar arrangements made with other large drugmakers. Companies such as Pfizer, Eli Lilly and Amgen have agreed to lower the prices of their medicines for the government’s Medicaid program for low-income people and for cash payers as part of the administration’s effort to bring U.S. prescription costs closer to those paid in other wealthy countries. The administration has emphasized that U.S. patients currently pay substantially more for prescription medicines, often nearly three times the amount charged in other developed nations, and has been pressing manufacturers to reduce prices to levels paid abroad.
According to a report published earlier in the day by the news outlet NOTUS, Regeneron has consented to cut Medicaid prices for both its existing medicines and those it develops in the future. The same report, citing a White House official, said Regeneron agreed to offer its cholesterol medication Praluent at a price of $225 and that the drug will be listed on the direct-to-consumer website TrumpRx.
Separately, Regeneron announced it has received regulatory approval for a gene therapy branded as Otarmeni for children with a rare form of hearing loss. The company said the therapy will be made available free of charge in the United States.
The article accompanying the announcement also included a promotional segment aimed at traders interested in Regeneron stock. That segment described a chart analysis service that claims to interpret charts visually and provide a complete trading plan - including suggested entry, stop-loss and profit-target levels - in under 60 seconds, and invited readers to try the chart analysis for REGN.
Key points
- White House will announce a pricing agreement with Regeneron at a Thursday afternoon event after a post by press secretary Karoline Leavitt on X.
- Regeneron is the last of 17 large pharmaceutical companies to sign a deal following letters from President Donald Trump in July; the company confirmed the announcement will occur at the event.
- The reported terms include reductions in Medicaid prices for current and future drugs, a $225 price for Praluent, and the provision of the newly approved gene therapy Otarmeni free in the U.S.
- The announcement details and implementation mechanisms for the pricing agreement have not been fully disclosed in this report - this leaves uncertainty about how price reductions will be applied across drugs and programs.
- The information about Medicaid price cuts and the $225 Praluent price was reported by NOTUS citing a White House official; the report’s details have not been independently confirmed within this article.
- Market reactions to the announcement are uncertain beyond the initial intraday stock movement; longer-term investor response will depend on the final terms and how broadly similar deals are enforced.